Scout literature and precedent review
Searches, structures, and summarizes scientific and regulatory precedent from sources including PubMed, ClinicalTrials.gov, and drugs@FDA so teams can work from a shared evidence base.
Unlearn provides AI software for clinical development teams, uniting trial planning, monitoring, and digital twin analysis in one connected platform.
Unlearn is a clinical development platform built around AI-generated digital twins, evidence review, trial simulation, and monitoring. The site frames the product as a connected workspace for teams that need to make trial decisions from the same evidence base rather than scattered documents, spreadsheets, and ad hoc analyses.
The platform is organized around three main workflows: planning, monitoring, and analysis. Trial Planning & Simulations helps teams review precedent, inspect historical data, and compare study designs before protocols are finalized. Advanced Trial Monitoring surfaces patient- and site-level anomalies during execution. Digital Twins support trial analyses by forecasting expected control outcomes for individual participants and using those forecasts in randomized, single-arm, open-label, interim, and retrospective settings.
Searches, structures, and summarizes scientific and regulatory precedent from sources including PubMed, ClinicalTrials.gov, and drugs@FDA so teams can work from a shared evidence base.
Explores harmonized clinical trial and real-world datasets to validate assumptions about populations, endpoint behavior, and benchmarks before design decisions are locked in.
Builds and compares trial-design scenarios across endpoints, eligibility criteria, sample size, and constraints, while keeping assumptions, evidence, and outputs linked for review.
Surfaces patient- and site-level anomalies using historical patient trajectories rather than generic cutoffs, helping teams focus review where signals are most relevant.
Generates AI forecasts of a participant’s expected control outcomes for use as digital twins in randomized, single-arm, open-label, interim, and retrospective analyses.
Can be deployed as a web application or in a sponsor’s cloud infrastructure, and the site says sponsors may also build custom digital twins in secure environments under their control.
Use the planning workspace to review precedent, inspect historical evidence, and compare study scenarios before finalizing a protocol. This fits teams that need to document rationale for endpoints, eligibility criteria, and sample size trade-offs.
Use digital twins as external comparators in early-stage or open-label studies when randomization is infeasible or when teams want more sensitive treatment comparisons. The site also describes them as useful for randomized trials that need smaller control arms or greater power.
Use advanced monitoring during study execution to surface unusual values, off-trajectory responders, and multivariate signals for patient- and site-level review ahead of the standard cycle.
Use the scenario tools to evaluate how different protocol choices change populations and expected outcomes, then preserve the evidence and rationale for governance discussions.
Use custom digital twin generators in secure sponsor environments when proprietary data should stay under sponsor control and the team needs a disease-specific model tuned to its own data.
Unlearn positions its platform for clinical development teams that need to make design, monitoring, and analysis decisions from the same evidence base. The trial planning workspace is described as useful before protocols are finalized, while digital twins and advanced monitoring support later-stage analysis and oversight.
The source pages describe three connected areas: Trial Planning & Simulations, Advanced Trial Monitoring, and Digital Twins. Trial planning brings together literature review, historical data exploration, and scenario simulation; monitoring surfaces patient- and site-level anomalies; digital twins provide AI-generated forecasts of expected control outcomes.
The site says Scout searches and summarizes precedent from sources such as PubMed, ClinicalTrials.gov, and drugs@FDA. Hindsight explores harmonized clinical trial and real-world datasets, and SimLab compares trial-design scenarios such as endpoints, eligibility criteria, sample size, and constraints.
Unlearn says its digital twins are AI-generated forecasts of an individual participant’s control outcomes and can be used as external comparators in early-stage and open-label studies, as well as in randomized trials. The site also says its methods are qualified by the EMA and aligned with current FDA guidance.
The pricing page returns a page-not-found response, so the source does not provide pricing, packaging, or plan details. For commercial information, the site directs visitors to contact the company.